Supraventricular Tachycardia

Published on 07/06/2015 by admin

Filed under Neonatal - Perinatal Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 3.3 (3 votes)

This article have been viewed 3719 times

22 Supraventricular Tachycardia

I. CASE

A 30-year-old African American woman, gravida 1, was referred at 25 weeks by the high-risk obstetrician for rapid fetal heart rate during a routine obstetrics appointment. The mother had Wolff–Parkinson–White (WPW) syndrome and had had successful catheter ablation. She is currently not on any antiarrhythmic medication.

A. Fetal echocardiography findings

D. Fetal management and counselling

1. Amniocentesis is not indicated. The risk from this procedure is higher than the chance of trisomy with SVT.

2. Initial management of the fetal SVT.

a. Hospital admission was advised for monitoring the fetal heart rate and the mother’s health during administration of antiarrhythmic medications.

b. The mother was fully evaluated by adult cardiology with a baseline electrocardiogram (ECG) and echocardiogram to exclude obvious cardiac pathology that would place her at risk in administering antiarrhythmic medications. Thyroid function testing was normal.

c. Management of the fetal SVT was discussed with the mother and her partner. It was explained that in more than 80% of patients, control of the dysrhythmia is possible, but occasionally this requires more than one medication and monitoring until the mother is on a sufficient dose of the medication that controls the fetal dysrhythmia.

d. With or without rhythm control, there is a small risk of a sudden fetal event or the development of fetal hydrops (particularly without control) as well as risks of other morbidities (e.g., stroke).

3. Daily fetal echo assessments included:

a. Progression of hydrops signs (pleural effusion, ascites, increasing pericardial fluid).

b. Increasing size indicating compromise of heart function.

c. Valve function for increasing degrees of tricuspid and mitral regurgitation. The dP/dt (change in pressure per change in time) can be assessed on AV valve regurgitation jets. Normal is greater than 1000 mm Hg per second, and a poor prognosis is associated with values less than 400 mm Hg per second.

d. Semilunar valve regurgitation, which is a sign of progression in myocardial dysfunction.

e. Myocardial function, which can be measured with the Tei index in sinus rhythm after conversion.

f. Venous Doppler assessment for signs of improvement.

4. Fetal therapy.

a. Baseline maternal 12-lead ECG was performed, which showed a prolonged PR interval of 0.25 seconds with no other abnormality and normal QTc.

b. The mother was tested (hematology) for hyperthyroidism and infection. Consultation with adult cardiology was obtained, and her exam and echocardiogram were normal.

c. Electrocardiogram.

d. Drug therapy.

e. Follow-up.

II. YOUR HANDY REFERENCE

A. Prevalence

1. The actual prevalence of fetal tachyarrhythmia is not known.

a. The most common fetal tachycardia is SVT, which accounts for 90% of fetal tachycardia.

b. The second most common form of fetal tachycardia is atrial flutter and is seen in 10% to 30% of patients. Atrial pulsations in the IVC at greater than 400 bpm are a clue to the diagnosis.

c. Ventricular tachycardia in the fetus is relatively rare and accounts for less than 5% of fetal tachycardia. One clue to this diagnosis is a tachycardia rate of less than 225 bpm with signs of congestive heart failure (CHF).

2. Fetal arrhythmia can occur at any gestational age, but it is most commonly seen after 24 weeks of pregnancy. Tachycardia before 20 weeks of gestation raises the likelihood of infection or maternal drug ingestion or hyperthyroidism.

3. The risk of tachycardia is highest in fetuses with multiple blocked atrial premature beats leading to a low ventricular rate (atrial bigeminy). The vast majority of fetuses with atrial and ventricular premature beats without tachycardia have uneventful prenatal and postnatal outcome. Intermittent SVT should be monitored to assess what portion of the whole day the fetus is in SVT (Fig. 22-3).

4. Fetal tachycardia is associated with structural cardiac anomalies in 1% to 5% of cases.

a. The most commonly described associations with SVT are Ebstein’s anomaly and myocardial tumors, particularly rhabdomyoma.

b. Myocardial tumors and cardiomyopathy may be present in fetal ventricular tachycardia.

D. Mechanisms of fetal arrhythmias

1. The definition of an abnormally fast heart rate depends on the gestational age of the fetus.

a. The fetal heart rates that have been observed in normal pregnancy are 90 bpm at 6 weeks, increasing to 160 to 180 bpm by 9 weeks.

b. The heart rate falls to 140 bpm ± 20 bpm by 20 weeks, and again to 130 bpm ± 20 bpm near term.

c. A fetal heart rate in excess of 180 bpm is abnormal.

2. The high incidence of atrioventricular reentry tachycardia (AVRT) or, similarly, unidirectional reciprocating accessory pathway tachycardia (URAP) during fetal and neonatal life and its decrease due to the spontaneous disappearance of SVT can suggest immaturity of the myocardium. In particular, these tachycardias suggest a delayed development of the annulus fibrosus and/or prolonged persistence of accessory AV pathways.

3. Fetal atrial flutter is rare, and atrial fibrillation to date has not been reported in a fetus.

a. Atrial flutter is generated within the atria by an atrial reentrant circuit and is observed mainly during the third trimester. This supports the hypotheses of an atrial macroreentry as an underlying mechanism of fetal atrial flutter.

b. It might resolve spontaneously or progress to hydrops and death.

c. Incessant heart rates as high as 300 bpm can lead to hydrops in 2 to 3 days (Fig. 22-4) and manifest umbilical venous pulsations.

4. The pathophysiology in SVT of the human fetus includes an impeded ventricular filling due to a short, inadequate diastolic period. This can alter the ventricular filling either directly or by changes in diastolic ventricular function due to inadequate oxygen supply by the reduced myocardial flow. Both mechanisms can elevate the venous pressure, resulting in increased rates of transcapillary fluid filtration into the interstitial space and significant reduction of lymphatic flow. This inadequate reduction in lymphatic drainage results in interstitial edema and finally hydrops (Box 22-1).

F. Classification of premature beats

1. An irregular fetal heart rate usually represents PACs or, less commonly, PVCs, which are beats that originate from the atrium or ventricle, respectively, from a site other than the normal central conduction system (e.g., sinus node).

2. PACs might or might not be conducted to the ventricle through the AV node.

a. When there is conduction through the AV node following a PAC, the pause that seems to occur between the PAC and the next sinus beat has the same time interval as two sequential sinus beats.

b. The PAC is thought to reset the pace of the sinus rhythm. Alternatively, the PAC may be blocked at the AV node as a result of the AV node’s having not fully recovered from the previous beat.

c. PACs can occur frequently, every two or three beats (atrial bigeminy or trigeminy, respectively).

d. Although there is beat-to-beat variability in sinus rhythm, it does not have such a distinct pattern as observed in atrial bigeminy or trigeminy.

3. PVCs are occasional extra systoles of ventricular origin in the fetus.

a. In premature ventricular beats, the ventricular contraction occurs before the atrial contraction by M-mode and can be easily documented.

b. There might or might not be ventriculoatrial conduction.

G. Classification of fetal tachycardias

1. General classification.

a. In extrauterine life, narrow QRS supraventricular tachycardia (SVT) is classified according to the relation of P waves to QRS complexes.

b. During intrauterine life, such classification is not possible due to the very low voltage of P waves on the currently available transmaternal fetal ECG. Thus, we rely on flow signals and mechanical action of the atria and ventricles to provide indirect clues to the arrhythmia mechanism.

c. Tachyarrhythmias can be divided into supraventricular (short and long VA tachycardias and atrial flutter), junctional (junctional ectopic tachycardia), and ventricular types.

2. Supraventricular tachyarrhythmias.

a. Fouron and colleagues (2003) suggest an echocardiographic classification using the measurement of AV and VA time intervals (Doppler velocimetry) (Fig. 22-5). This measurement shows the relationship between the atrial (beginning of the a wave on the SVC or mitral inflow Doppler) and ventricular contractions (beginning of the aortic wave).

b. Classification.

       (a) Concealed accessory pathway.

       (a) Sinus tachycardia is a long VA tachyarrhythmia.

3. Junctional ectopic tachycardia.

a. In this tachyarrhythmia, the atrial contractions can occur simultaneously with the ventricular contractions.

b. There is usually a warm-up and slow-down period.

c. This is a very rare form of fetal SVT.

4. Ventricular tachycardia.

a. Prenatal ventricular tachycardia is very rare but occasionally may be seen in isolation, in association with cardiomyopathies and tumors, long QT syndrome, and in myocardial ischemia.

b. It may be a manifestation of long-QT syndrome, although this diagnosis is more often associated before birth with persistent fetal bradycardia.

c. There may or may not be 1:1 conduction in ventricular tachycardia. If there is not, which is most common, the atrial rates are slower than the ventricular rates.

H. Ultrasound and echocardiographic assessment of dysrhythmias

1. M-mode echocardiography.

a. To evaluate cardiac rhythm by M-mode, the cursor is placed across the wall of the right atrium (particularly the right atrial appendage) and through one of the ventricles.

b. This technique demonstrates the relationship of atrial to ventricular contractions, and from this mechanical assessment the atrial and ventricular activation can be inferred.

c. This method is used to evaluate all types of fetal arrhythmias.

2. Doppler assessment of fetal dysrhythmias.

a. Pulsed Doppler interrogation may be used to determine the mechanism of an arrhythmia.

b. At times, simultaneous Doppler interrogation of the LV inflow and outflow can also assist in defining the mechanism of an arrhythmia, but there is potential for error in this technique when there is no flow through the AV valve as a consequence of ventricular contraction.

c. Doppler assessment of umbilical artery flow is a rapid method for determining ventricular rate.

d. Doppler assessment of systemic veins or ductus venosus is a rapid way to determine atrial rate.

e. Doppler assessment of umbilical vein: Normally, this blood flow velocity pattern is flat, but in SVT with heart failure, pulsations may be transmitted back to the cord vein.

3. Ultrasonographic investigation of fetal arrhythmia.

a. With M-mode, atrial and ventricular depolarizations are identified by their mechanical consequences.

b. Limitations of M-mode.

c. With Doppler, atrial and ventricular depolarizations are identified by their hemodynamic consequences.

d. Drawbacks with both M-mode and Doppler approaches in electromechanical delay and isometric contraction time are included in the AV interval measurement.

e. For more details on ultrasonographic investigation of fetal arrhythmia, see Table 22-1 and Figures 22-6 to 22-9.

4. Fetal magnetocardiography.

a. This system can detect the minute magnetic fields set up by the electrical discharge from the conducting tissue.

b. Processing of the signal allows separation of the maternal and fetal signals.

c. AV dissociation can be confirmed by identifying the P and R waves (Fig. 22-10).

5. Fetal electrocardiography: With current technology, about 60% of fetuses can have averaged ECG tracings to determine the AV relation and the Q-T interval.

6. Fetal ECG monitor (FEMO) and Qnetics data.

a. With irregular arrhythmias, this technique performs poorly.

b. At ventricular rates greater than 200 bpm or within the range of the maternal heart rates, assessment of dysrhythmias is not always possible with programs that are currently available.

TABLE 22-1 ULTRASONOGRAPHIC INVESTIGATION OF FETAL ARRHYTHMIA II

Arrhythmia M-Mode Doppler Sampling Site
PAC Early atrial wall contraction LV inflow/outflow: Increase in E wave amplitude (E+PAC) and pause (Fig. 22-6). SVC-Ao Doppler shows an early a wave, occurring earlier than previous sinus beat a waves With (conducted) or without (blocked) ventricular outflow or aortic flow signals
PVC Early ventricular wall contraction (with or without ejection); normal atrial wall movement
SVT 1:1 atrial-ventricular wall movements; high rate >220 bpm

Flutter 2:1 AV conduction with atrial wall contraction at ≥400 bpm and ventricular wall contraction at 1/2 the atrial rate

CHB Slow ventricular rate with normal, unrelated atrial rate

Ao, aorta; AV, atrioventricular; CHB, complete heart block; PAC, premature atrial contractions; PVC, premature ventricular contractions; SVC, superior vena cava; SVT, supraventricular tachycardia.

K. Antenatal treatment of fetal tachyarrhythmias (Box 22-2)

1. A multidisciplinary team effort is strongly recommended in the treatment of fetal tachyarrhythmias involving excellent collaboration between perinatal and obstetric, pediatric and fetal cardiology, and neonatal staff. This ensures not only better prenatal care but also anticipation of postnatal issues.

2. Intervention for fetal tachyarrhythmias should be considered in fetuses with:

a. Evidence of cardiovascular compromise (some degree of hydrops). In such fetuses, immediate initiation of therapy is critical because they are at the highest risk for mortality and morbidity.

b. Risk of cardiovascular compromise.

3. How to intervene.

a. Maternal–transplacental therapy is the treatment strategy of choice for most cases because it is effective in the majority of hydropic fetuses.

b. Transumbilical therapy.

c. Fetal intramuscular therapy.

4. Medications that can be used in fetal tachyarrhythmias.

a. Table 22-2 outlines the various medications that have been used successfully to treat fetal tachyarrhythmias. As observed postnatally, no one mediation is effective for all fetuses.

b. In determining which medication to use, one should consider its efficacy for a given dysrhythmia as well as the degree of fetal compromise.

c. Hydropic fetuses can require two or more medications. Often digoxin is used in addition to a stronger medication, such as sotalol, amiodarone, or flecainide, given the negative inotropic effects of these stronger medications.

d. Because there is conversion to sinus rhythm, the fetus might have episodes of bradycardia. Documentation of the mechanism of bradycardia is critical because often it is due to atrial premature beats with AV block (which suggests the medication is working), is usually well tolerated, and should not be an indication for urgent delivery.

5. Immediate perinatal and postnatal management of newborn arrhythmias.

a. Delivery of an affected infant with SVT should be planned through the collaborative efforts and communication among the perinatologist or obstetrician, neonatologists, and cardiologist to be certain the best timing and approach are chosen and the immediate neonatal management is appropriate.

b. With persistent SVT, it may be difficult to monitor the fetus before delivery, given the lack of beat-to-beat variability, and thus some obstetricians consider cesarean section. Early delivery or preterm delivery may be necessary if, despite reasonable attempts at maternal–transplacental or transumbilical therapy, there is inadequate control of the SVT, particularly if the fetus is becoming increasingly compromised.

c. With therapeutic conversion to sinus rhythm, delivery should probably still take place where the infant can be best managed by pediatricians and pediatric subspecialists because the infant could spontaneously convert back into the SVT at delivery or within hours of delivery.

d. At delivery, if the infant is in SVT, the treatment should depend on how compromised the infant is from a cardiovascular standpoint.

e. Once the baby is stable, a baseline 12-lead ECG in and out of the tachyarrhythmia is important to further document the mechanism. For instance, the p wave axis can be very useful in diagnosing concealed pathway SVT, which is usually the reverse of a normal p wave axis in sinus rhythm due to the retrograde conduction, and in diagnosing ectopic atrial tachycardia.

f. SVT (heart rate on monitor of 220-300 bpm).

g. In atrial flutter, the flutter wave might not be visible.

h. Frequent premature contraction.

III. TAKE-HOME MESSAGE

REFERENCES

Fouron JC, Fournier A, Proulx F, et al. Management of fetal tachyarrhythmia based on superior vena cava/aorta Doppler flow recordings. Heart. 2003;89(10):1211-1216.

Frohn-Mulder IM, Stewart PA, Witsenburg M, et al. The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia. Prenat Diagn. 1995;15(13):1297-1302.

Hansmann M, Gembruch U, Bald R, et al. Fetal tachyarrhythmias: Transplacental and direct treatment of the fetus—a report of 60 cases. Ultrasound Obstet Gynecol. 1991;1(3):162-168.

Li Z, Strasburger JF, Cuneo BF, et al. Giant fetal magnetocardiogram P waves in congenital atrioventricular block: A marker of cardiovascular compensation? Circulation. 2004;110(15):2097-2101.

Massumi RA. Familial Wolff–Parkinson–White syndrome with cardiomyopathy. Am J Med. 1967;43:951-955.

Schade RP, Stoutenbeek P, de Vries LS, Meijboom EJ. Neurological morbidity after fetal supraventricular tachyarrhythmia. Ultrasound Obstet Gynecol. 1999;13(1):43-47.

Simpson JM, Sharland GK. Fetal tachycardias: management and outcome of 127 consecutive cases. Heart. 1998;79(6):576-581.

Sonesson SE, Fouron JC, Wesslen-Eriksson E, et al. Foetal supraventricular tachycardia treated with sotalol. Acta Paediatr. 1998;87(5):584-587.

Strasburger JF, Cuneo BF, Michon MM, et al. Amiodarone therapy for drug-refractory fetal tachycardia. Circulation. 2004;109(3):375-379.

Van Engelen AD, Weijtens O, Brenner JI, et al. Management outcome and follow-up of fetal tachycardia. J Am Coll Cardiol. 1994;24(5):1371-1375.

Vidaillet HJJr, Pressley JC, Henke E, et al. Familial occurrence of accessory atrioventricular pathways (preexcitation syndrome). N Engl J Med. 1987;317:65-69.

Wheeler T, Murrills A. Patterns of fetal heart rate during normal pregnancy. Br J Obstet Gynaecol. 1978;85(1):18-27.

Zales VR, Dunnigan A, Benson DWJr. Clinical and electrophysiologic features of fetal and neonatal paroxysmal atrial tachycardia resulting in congestive heart failure. Am J Cardiol. 1988;62(4):225-228.